Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Outline of Final Research Achievements |
Immune-biomarkers and -assays are important for development of cancer immunotherapy to monitor immune induction following immunotherapy, and to evaluate anti-tumor effects early after immunotherapy. We characterized status of immune cells, cytokines, chemokines and other immunosuppressive molecules in recurrent malignant glioma patients who received vaccinations of VEGF receptor peptides. Peripheral blood samples from patients who demonstrated positive radiologic response or stable disease revealed superior VEGFR-specific CTL reactivity and lower level of serum VEGF compared to samples from other patients with progressing malignant glioma. These data indicate that these parameters may be potential immune-biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines.
|